OCUGEN INC. - COMMON STOCK

0.7041

20-February-25 13:31:30

15 minutes delayed

Stocks

+0.0083

+1.19%

Today's range

0.6717 - 0.7070

ISIN

N/A

Source

NASDAQ

Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit

05 Sep 2024 07:00:07 By Nasdaq GlobeNewswire
Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

03 Sep 2024 07:30:42 By Nasdaq GlobeNewswire
Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy

28 Aug 2024 06:30:32 By Nasdaq GlobeNewswire
Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication

26 Aug 2024 07:02:41 By Nasdaq GlobeNewswire
Ocugen Provides Business Update with Second Quarter 2024 Financial Results

08 Aug 2024 06:45:00 By Nasdaq GlobeNewswire
Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa

05 Aug 2024 06:30:33 By Nasdaq GlobeNewswire
Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock

02 Aug 2024 15:22:33 By Nasdaq GlobeNewswire
Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock

31 Jul 2024 21:15:46 By Nasdaq GlobeNewswire
Ocugen, Inc. Announces Proposed Public Offering of Common Stock

31 Jul 2024 16:15:04 By Nasdaq GlobeNewswire
Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results

29 Jul 2024 07:02:15 By Nasdaq GlobeNewswire
Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy

25 Jul 2024 06:30:20 By Nasdaq GlobeNewswire
Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease

21 Jun 2024 07:00:00 By Nasdaq GlobeNewswire
Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication

20 Jun 2024 06:30:31 By Nasdaq GlobeNewswire
Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy

31 May 2024 08:36:49 By Nasdaq GlobeNewswire
Ocugen to Present at BIO International Convention 2024

29 May 2024 07:15:00 By Nasdaq GlobeNewswire
Ocugen Set to Join Russell 3000® Index Effective June 28, 2024

28 May 2024 07:02:39 By Nasdaq GlobeNewswire
Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024

20 May 2024 07:00:52 By Nasdaq GlobeNewswire
Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy

15 May 2024 06:30:00 By Nasdaq GlobeNewswire
Ocugen Provides Business Update with First Quarter 2024 Financial Results

14 May 2024 08:00:25 By Nasdaq GlobeNewswire
Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock

10 May 2024 16:05:06 By Nasdaq GlobeNewswire

<<
<
1
2
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.